WO2005107706A3 - Biodegradable intravitreal tyrosine kinase inhibitors implants - Google Patents

Biodegradable intravitreal tyrosine kinase inhibitors implants Download PDF

Info

Publication number
WO2005107706A3
WO2005107706A3 PCT/US2005/014649 US2005014649W WO2005107706A3 WO 2005107706 A3 WO2005107706 A3 WO 2005107706A3 US 2005014649 W US2005014649 W US 2005014649W WO 2005107706 A3 WO2005107706 A3 WO 2005107706A3
Authority
WO
WIPO (PCT)
Prior art keywords
implants
tyrosine kinase
kinase inhibitors
biodegradable intravitreal
eye
Prior art date
Application number
PCT/US2005/014649
Other languages
French (fr)
Other versions
WO2005107706A2 (en
Inventor
Patrick M Hughes
Thomas Malone
Gerald Devries
Jeffrey L Edelman
Joan-En Chang-Lin
Jane Guo Shiah
Thierry Navagglioli
Lon T Spada
Wendy M Blanda
Original Assignee
Allergan Inc
Patrick M Hughes
Thomas Malone
Gerald Devries
Jeffrey L Edelman
Joan-En Chang-Lin
Jane Guo Shiah
Thierry Navagglioli
Lon T Spada
Wendy M Blanda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Patrick M Hughes, Thomas Malone, Gerald Devries, Jeffrey L Edelman, Joan-En Chang-Lin, Jane Guo Shiah, Thierry Navagglioli, Lon T Spada, Wendy M Blanda filed Critical Allergan Inc
Publication of WO2005107706A2 publication Critical patent/WO2005107706A2/en
Publication of WO2005107706A3 publication Critical patent/WO2005107706A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Abstract

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
PCT/US2005/014649 2004-04-30 2005-04-27 Biodegradable intravitreal tyrosine kinase inhibitors implants WO2005107706A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/837,361 2004-04-30
US10/837,361 US7771742B2 (en) 2004-04-30 2004-04-30 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

Publications (2)

Publication Number Publication Date
WO2005107706A2 WO2005107706A2 (en) 2005-11-17
WO2005107706A3 true WO2005107706A3 (en) 2006-01-12

Family

ID=34967821

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/014811 WO2005112884A1 (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer
PCT/US2005/014649 WO2005107706A2 (en) 2004-04-30 2005-04-27 Biodegradable intravitreal tyrosine kinase inhibitors implants

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014811 WO2005112884A1 (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer

Country Status (7)

Country Link
US (7) US7771742B2 (en)
EP (2) EP1742610B1 (en)
JP (5) JP2007535556A (en)
AU (2) AU2005244780B2 (en)
BR (1) BRPI0509461A (en)
CA (2) CA2838526C (en)
WO (2) WO2005112884A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968766B2 (en) 2004-04-30 2015-03-03 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US9233070B2 (en) 2004-04-30 2016-01-12 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP1490356B1 (en) * 2002-04-03 2013-02-27 Allergan, Inc. (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
ES2318453T3 (en) 2004-01-20 2009-05-01 Allergan, Inc. COMPOSITIONS FOR LOCALIZED EYE THERAPY, WHICH INCLUDE, PREFERENCE, ACETONID TRIAMCINOLONE AND HIALURONIC ACID.
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8455656B2 (en) * 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
JP2008535847A (en) * 2005-04-08 2008-09-04 サーモディクス，インコーポレイティド Sustained release implant for subretinal delivery
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
RU2473565C2 (en) 2006-04-07 2013-01-27 Аерпио Терапетикс, Инк. HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPβ), AND USE THEREOF
JP5445130B2 (en) * 2006-05-02 2014-03-19 メディバス エルエルシー Delivery of ophthalmic drugs to the exterior or interior of the eye
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008020931A2 (en) * 2006-08-08 2008-02-21 Peak Biosciences, Inc. Device for delivery of anti-cancer agents to tissue
CA2668814A1 (en) * 2006-11-09 2008-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
EP2178502A2 (en) 2007-06-21 2010-04-28 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009143288A1 (en) * 2008-05-20 2009-11-26 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
JP5809169B2 (en) * 2010-01-22 2015-11-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Therapeutic drug sustained release intraluminal implant
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9814773B2 (en) * 2011-06-10 2017-11-14 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CN103748139B (en) 2011-06-23 2016-08-17 帝斯曼知识产权资产管理有限公司 For delivering the micron particle comprising biodegradable polyester-amide copolymer or the nano-particle of bioactivator
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CN104936620B (en) 2012-01-19 2019-08-09 约翰霍普金斯大学 Enhance the nanoparticle composite of transmucosal
US9388176B2 (en) 2012-03-12 2016-07-12 Allergan, Inc. Method of treating conditiions with kinase inhibitors
EP2825537B1 (en) 2012-03-12 2017-01-04 Allergan, Inc. Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf
WO2013138343A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
AU2013256130B2 (en) 2012-05-03 2017-12-21 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CA2939952C (en) 2013-03-05 2022-03-22 Morgan V. Fedorchak Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US20140271772A1 (en) * 2013-03-15 2014-09-18 Barry J. Margulies Biodegradable subcutaneous implants and methods of making
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
MX2016009312A (en) 2014-01-16 2017-01-06 Ontogenesis Llc Compositions and methods for the treatment of intraocular neovascularization and/or leakage.
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
JP6483148B2 (en) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド HPTP-β inhibitor
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
NZ733130A (en) * 2014-12-15 2018-09-28 Univ Johns Hopkins Sunitinib formulations and methods for use thereof in treatment of ocular disorders
CN107106509B (en) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 Drug delivery system for delivering acid sensitive drugs
WO2016123125A1 (en) 2015-01-27 2016-08-04 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN107921036A (en) * 2015-05-29 2018-04-17 优势医疗公司 For reducing the composition and method of visual loss
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
KR20180058758A (en) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. Compounds and compositions for the treatment of ocular disorders
KR20180054677A (en) 2015-09-23 2018-05-24 에르피오 세러퓨틱스 인코포레이티드 Methods of Treating Guidance Pressure with Activator of TIE-2
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN108367079B (en) 2015-11-12 2022-11-22 灰色视觉公司 Aggregated microparticles for therapy
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (en) 2016-05-10 2019-04-02 C4医药公司 Heterocycle degron body for target protein degradation
US20170342383A1 (en) 2016-05-27 2017-11-30 Corning Incorporated Lithium disilicate glass-ceramic compositions and methods thereof
US10059621B2 (en) 2016-05-27 2018-08-28 Corning Incorporated Magnetizable glass ceramic composition and methods thereof
US10647962B2 (en) 2016-05-27 2020-05-12 Corning Incorporated Bioactive aluminoborate glasses
US10751367B2 (en) 2016-05-27 2020-08-25 Corning Incorporated Bioactive glass microspheres
US10676713B2 (en) 2016-05-27 2020-06-09 Corning Incorporated Bioactive borophosphate glasses
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
MX2018016046A (en) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders.
EP3478294A4 (en) 2016-07-01 2020-06-10 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
CN110662543A (en) 2017-03-23 2020-01-07 灰色视觉公司 Medicaments and compositions for treating ocular diseases
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019089573A1 (en) 2017-10-30 2019-05-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
CN111405913A (en) 2017-11-28 2020-07-10 康宁股份有限公司 Bioactive glass compositions and dentinal hypersensitivity repair
WO2019108557A1 (en) 2017-11-28 2019-06-06 Corning Incorporated Bioactive borate glass and methods thereof
WO2019108558A1 (en) 2017-11-28 2019-06-06 Corning Incorporated High liquidus viscosity bioactive glass
US10857259B2 (en) 2017-11-28 2020-12-08 Corning Incorporated Chemically strengthened bioactive glass-ceramics
KR20210018199A (en) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 Cerevlon binder for decomposition of Ikaros
JP2021535112A (en) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド Pharmaceutical compounds for the treatment of medical disorders of complement D factor
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
AU2020283135A1 (en) * 2019-05-31 2022-01-06 Dose Medical Corporation Bioerodible polyester polymer implants and related methods of use
BR112021026265A2 (en) 2019-06-27 2022-06-14 Layerbio Inc Eye device delivery methods and systems
WO2021237096A1 (en) * 2020-05-21 2021-11-25 Graybug Vision, Inc. Durable implants and microparticles for long-term ocular therapy
CN111861124B (en) * 2020-06-18 2023-07-25 汕头大学 Identifiable performance evaluation method, identifiable performance evaluation system and storage medium applicable to injection molding machine
KR20230052915A (en) * 2020-08-18 2023-04-20 오크우드 레버러토리즈, 엘엘씨 Microsphere Formulations Containing Ketamine and Methods of Making and Using The Same
JP2023546112A (en) 2020-10-15 2023-11-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
WO2004112748A2 (en) * 2003-06-16 2004-12-29 Bausch & Lomb Incorporated Rate controlled release of a pharmaceutical agent in a biodegradable device

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
SE390255B (en) 1974-02-18 1976-12-13 N G Y Torphammar RELEASE DEVICE PREFERRED FOR A SAFETY BELT IN A VEHICLE
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966749A (en) 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4052505A (en) 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4057619A (en) 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4396625A (en) 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (en) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Aperture control circuit for TTL auto strobe
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (en) 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Cooking and roasting utensils with lids provided with metal handles, in particular stainless steel handles
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4675338A (en) 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4693885A (en) 1984-07-18 1987-09-15 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
FR2577509B1 (en) 1985-02-21 1987-05-07 Nirvana Espar Systems Sa SAILING BOAT MAT
US4656186A (en) 1985-04-30 1987-04-07 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
FR2594438B1 (en) 1986-02-14 1990-01-26 Labaz Sanofi Nv INDOLIZINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING SAME
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4981871A (en) 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
DE3734223A1 (en) 1987-10-09 1989-04-20 Boehringer Ingelheim Kg IMPLANTABLE, BIODEGRADABLE ACTIVE SUBSTANCE RELEASE SYSTEM
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
EP1224935A3 (en) 1988-09-06 2003-03-26 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5595945A (en) * 1989-01-05 1997-01-21 The United States Of America As Represented By The Department Of Energy Ceramic composite coating
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5268178A (en) 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5503721A (en) 1991-07-18 1996-04-02 Hri Research, Inc. Method for photoactivation
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5100431A (en) 1990-09-27 1992-03-31 Allergan, Inc. Single stitch suture needle and method
KR0185215B1 (en) 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
KR0145278B1 (en) 1991-06-21 1998-07-15 브루스 엠. 에이센 Pharmaceutical formulations of osteogenic proteins
US5356629A (en) 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
IT1263116B (en) 1992-04-09 1996-07-30 Rotta Research Lab BASIC DERIVATIVES OF GLUTAMIC ACID AND ASPARTIC ACID, PROCEDURE FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
US5655832A (en) 1992-04-16 1997-08-12 Tir Technologies, Inc. Multiple wavelength light processor
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (en) 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraocular lens arrangement for astigmatism correction
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6270492B1 (en) 1994-09-09 2001-08-07 Cardiofocus, Inc. Phototherapeutic apparatus with diffusive tip assembly
ATE198152T1 (en) 1994-09-30 2001-01-15 Takeda Chemical Industries Ltd ORAL MEDICINAL PREPARATION WITH DELAYED RELEASE OF ACTIVE INGREDIENTS
JPH08151322A (en) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd Oral sustained release agent
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
JP2002511868A (en) 1997-06-30 2002-04-16 アラーガン・セイルズ・インコーポレイテッド Calcium blockers for treating proliferative vitreoretinopathy
EP1003569B1 (en) 1997-08-11 2004-10-20 Allergan, Inc. Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture
US6271220B1 (en) 1998-03-11 2001-08-07 Allergan Sales, Inc. Anti-angiogenic agents
JP2002506028A (en) * 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン Use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
ATE428345T1 (en) 1998-07-09 2009-05-15 Curelight Medical Ltd DEVICE AND METHOD FOR EFFECTIVE HIGH-ENERGY PHOTODYNAMIC THERAPY OF ACNE VULGARIS AND SEBORRHEA
DE69924749T2 (en) 1998-11-20 2006-04-27 The University Of Connecticut, Farmington Generically integrated implantable potentiostat remote sensing device for electrochemical probes
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
JP4920134B2 (en) * 1999-05-07 2012-04-18 ジョンズ ホプキンス ユニヴァーシティ スクール オヴ メディシン Use of protein tyrosine kinase pathway inhibitors in the treatment of eye disorders
US6290713B1 (en) 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy
US6317616B1 (en) 1999-09-15 2001-11-13 Neil David Glossop Method and system to facilitate image guided surgery
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6319273B1 (en) 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
AU3497901A (en) 2000-02-10 2001-08-20 Massachusetts Eye & Ear Infirm Methods and compositions for treating conditions of the eye
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6357568B1 (en) 2000-09-27 2002-03-19 Shou Mao Chen Structure for protecting a luggage shell
AU2002248284A1 (en) 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
DE60114229T2 (en) 2000-11-29 2006-07-06 Allergan, Inc., Irvine PREVENTING TRANSPLANT DISCHARGE IN THE EYE
US6595945B2 (en) 2001-01-09 2003-07-22 J. David Brown Glaucoma treatment device and method
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
EP1418903A2 (en) * 2001-04-23 2004-05-19 The Board of Regents of the University of Texas System Prostanoids augment ocular drug penetration
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6713268B2 (en) 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
AU2002341881B2 (en) 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6559173B1 (en) * 2001-09-27 2003-05-06 Allergan, Inc. 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
EP1490356B1 (en) * 2002-04-03 2013-02-27 Allergan, Inc. (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US6699863B1 (en) * 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8455656B2 (en) * 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
BRPI0510485A (en) 2004-04-30 2007-11-13 Allergan Inc biodegradable intravitreal tyrosine kinase inhibitor implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
CA2602440A1 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
JP2010510242A (en) * 2006-11-16 2010-04-02 アラーガン、インコーポレイテッド Sulfoximine as a kinase inhibitor
US8642067B2 (en) * 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
WO2004112748A2 (en) * 2003-06-16 2004-12-29 Bausch & Lomb Incorporated Rate controlled release of a pharmaceutical agent in a biodegradable device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY 19 May 1989 (1989-05-19), "RN-120685-11-2", XP002336813 *
LAIRD ET AL: "Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 12, no. 1, January 2003 (2003-01-01), pages 51 - 64, XP002328206, ISSN: 1354-3784 *
MERKLI A ET AL: "USE OF INSOLUBLE BIODEGRADABLE POLYMERS IN OPHTHALMIC SYSTEMS FOR THE SUSTAINED RELEASE OF DRUGS", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 41, no. 5, 1 October 1995 (1995-10-01), pages 271 - 283, XP000535194, ISSN: 0939-6411 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968766B2 (en) 2004-04-30 2015-03-03 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US9233070B2 (en) 2004-04-30 2016-01-12 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants

Also Published As

Publication number Publication date
CA2838526C (en) 2016-11-29
JP2014156496A (en) 2014-08-28
JP5582680B2 (en) 2014-09-03
US8481069B2 (en) 2013-07-09
WO2005107706A2 (en) 2005-11-17
US9056045B2 (en) 2015-06-16
US20080260803A1 (en) 2008-10-23
US20130330395A1 (en) 2013-12-12
US20050244470A1 (en) 2005-11-03
EP1742610B1 (en) 2013-06-12
JP5985536B2 (en) 2016-09-06
AU2005244780B2 (en) 2010-03-25
JP5586637B2 (en) 2014-09-10
CA2565182C (en) 2014-07-08
BRPI0509461A (en) 2007-09-04
US8409607B2 (en) 2013-04-02
US20080254096A1 (en) 2008-10-16
US8968766B2 (en) 2015-03-03
AU2005240093B2 (en) 2011-05-12
AU2005240093A1 (en) 2005-11-17
EP1750665A1 (en) 2007-02-14
JP2011224408A (en) 2011-11-10
US20120258163A1 (en) 2012-10-11
US20050244477A1 (en) 2005-11-03
EP1742610A1 (en) 2007-01-17
JP5608138B2 (en) 2014-10-15
WO2005112884A1 (en) 2005-12-01
JP2007535556A (en) 2007-12-06
EP1750665B1 (en) 2012-07-11
US7771742B2 (en) 2010-08-10
CA2838526A1 (en) 2005-12-01
CA2565182A1 (en) 2005-12-01
US8465778B2 (en) 2013-06-18
JP2012067143A (en) 2012-04-05
AU2005244780A1 (en) 2005-12-01
US8404267B2 (en) 2013-03-26
US20130210862A1 (en) 2013-08-15
JP2007535567A (en) 2007-12-06

Similar Documents

Publication Publication Date Title
WO2005107706A3 (en) Biodegradable intravitreal tyrosine kinase inhibitors implants
TW200605918A (en) Biodegradable intravitreal tyrosine kinase implants
TW200603775A (en) Anti-excitotoxic sustained release intraocular implants and related methods
BRPI0510471A (en) estradiol derivative or a stratopone derivative containing constant release intraocular implant as well as related manufacturing methods
WO2005110368A8 (en) Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2005110367A3 (en) Sustained release intraocular implants and methods for preventing retinal dysfunction
NZ595349A (en) Nasolacrimal drainage system implants for drug therapy with drug core within sheath and expandable body
WO2008070402A3 (en) Intraocular drug delivery systems
WO2006031658A3 (en) Therapeutic lacrimal canalicular inserts and related methods
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
CA3010374A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants
WO2010056598A3 (en) Biodegradable alpha-2 adrenergic agonist polymeric implants
WO2006050045A3 (en) Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2007150018A3 (en) Steroid-containing sustained release intraocular implants and related methods
WO2004066979A3 (en) Sustained release device and method for ocular delivery of adrenergic agents
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
WO2008057867A3 (en) Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2006017347A3 (en) Opthalmic compositions and methods for treating ophthalmic conditions
WO2009137085A3 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2004066980A3 (en) Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
EP4252725A3 (en) Ocular implant containing a tyrosine kinase inhibitor
WO2007008262A3 (en) Method and apparatus for lacrimal canal obstruction
WO2005105037A8 (en) Use of a viscoelastic composition for treating increased intraocular pressure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase